Objective: The aim: To substantiate the selection of a substitution therapy medication for dry eye syndrome treatment in patients wearing different kinds of contact lenses.

Patients And Methods: Materials and methods: A structural analysis of the assortment of substitution therapy medications for dry eye syndrome treatment as well as a content analysis of the information given in the labelling claims of various substitution therapy medication was conducted. Than they were segmented using the criteria of whether the substitution therapy medications may be used in patients with dry eye syndrome who wear contact lenses.

Results: Results: The labelling claims of 82.36% substitution therapy medications registered in Ukraine assortment contain information on either full or partial compatibility with contact lenses. The use of 11.76% of the assortment is impossible for patients wearing soft contact lenses, while patients wearing hard contact lenses need to wait for some period of time (15-20 min) before putting contact lenses back on.

Conclusion: Conclusions: The pharmaceutical market of Ukraine is characterized by a wide assortment of substitution therapy medications for dry eye syndrome treatment, which can be used in patients wearing contact lenses. Based on the data received, it has been determined that 70.59% of substitution therapy medications are compatible with contact lenses of all types and only the use of 8.82% of the substitution therapy medications assortment is contraindicated for dry eye syndrome treatment in patients wearing contact lenses.

Download full-text PDF

Source

Publication Analysis

Top Keywords

substitution therapy
36
contact lenses
28
dry eye
24
eye syndrome
24
therapy medications
24
syndrome treatment
20
patients wearing
20
treatment patients
16
therapy medication
12
contact
10

Similar Publications

Background: Direct acting antivirals (DAAs) have demonstrated remarkable efficacy, in achieving hepatitis C viral (HCV) elimination rates higher than 90%. One particular concern associated with treatment failure is the emergence of resistance associated substitutions (RASs) in the genome. The occurrence of RASs highlights the adaptability and resilience of the HCV.

View Article and Find Full Text PDF

Human carbonic anhydrase IX (CAIX) plays a key role in maintaining pH homeostasis of malignant neoplasms, thus creating a favorable microenvironment for the growth, invasion, and metastasis of tumor cells. Recent studies have established that inhibition of CAIX expressed on the surface of tumor cells significantly increases the efficacy of classical chemotherapeutic agents and makes it possible to suppress the resistance of tumor cells to chemotherapy, as well as to increase their sensitivity to drugs (in particular, to reduce the required dose of cytostatic agents). In this work, we studied the ability of new CAIX inhibitors based on substituted 1,2,4-oxadiazole-containing primary aromatic sulfonamides, to potentiate the cytostatic effect of gefitinib (selective inhibitor of epidermal growth factor receptor tyrosine kinase domain) under hypoxic conditions.

View Article and Find Full Text PDF

Hydroxyapatite (HA) is an important constituent of natural bone. The properties of HA can be enhanced with the help of various ionic substitutions in the crystal lattice of HA. Iron (Fe) is a vital element present in bones and teeth.

View Article and Find Full Text PDF

Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection.

Viruses

December 2024

Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Achieving HBsAg seroclearance is a key goal in treating chronic hepatitis B virus (HBV) infection but remains difficult with nucleos(t)ide analogues (NAs). Tenofovir alafenamide fumarate (TAF), a recommended NA for managing chronic HBV infection (CHB), has uncertain effects on HBsAg levels and potential adverse events when used long-term after switching from entecavir (ETV). We retrospectively evaluated 77 CHB patients, including 47 who switched from ETV to TAF with a median follow-up of 40 months post-switch and a median of 60 months of HBsAg monitoring pre-switch.

View Article and Find Full Text PDF

Identification of a New Pentafluorosulfanyl-Substituted Chalcone with Activity Against Hepatoma and Human Parasites.

Pharmaceuticals (Basel)

January 2025

Institute of Physiology, Charité-Universitätsmedizin Berlin, Corporate Member of the Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117 Berlin, Germany.

Background/objectives: New drugs are required for the treatment of liver cancers and protozoal parasite infections. Analogs of the known anticancer active and antileishmanial 2',4',6'-trimethoxychalcone SU086 were prepared and investigated.

Methods: The chalcones were prepared according to the Claisen-Schmidt condensation protocol and analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!